This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Market Preview: Hitting Pause

BMO Capital Markets noted on Monday that the selling pressure on the stock has been particularly fierce of late as it's down more than 20% since March 19's close at $6.48 based on Friday's finish at $5.13. The firm has a market perform, or hold rating, on SUPERVALU with an $8 price target vs. Monday's close at $5.32

"[E]ven with the 35% short interest, ~7% dividend yield, reasonable valuation and ample liquidity, there appears to be no support (or no incremental buyer) for the stock," said the firm, which has a market perform rating on SUPERVALU and is expecting earnings of 39 cents a share in the quarter.

"We are hopeful 4Q12 represents a trough in performance and hope the company can present investors with meaningful positive data points to appease existing investors and generate an incremental buyer, because despite significant company specific and macro challenges, we see no liquidity issues for the foreseeable future, so believe the excessive selling pressure has been unwarranted," BMO continued.

SUPERVALU's forward price-to-earnings ratio sits at 4.45X vs. 9.49X for Kroger (KR), and 9.22X for Safeway (SWY), but bulls are still few and far between with just three of the 18 analysts covering SUPERVALU at either strong buy (1) or buy (2) and the rest split between hold (12), underperform (2) and sell (1).

Check out TheStreet's quote page for SUPERVALU for year-to-date share performance, analyst ratings, earnings estimates and much more.

The economic data doesn't pick up until late in the week with the producer price index and consumer price index for March until Thursday and Friday respectively, and the first read from the University of Michigan on consumer sentiment in April due on Friday as well.

Tuesday features wholesale inventories for February at 10 a.m. ET. The consensus is for an increase of 0.5%, according to, but Wall Street likely won't get too excited one way or another, given how old the data is.

And finally, Harmonic (HLIT - Get Report) and VIVUS (VVUS - Get Report) were both trading lower in Monday's after-hours action.

A regulatory setback sent shares of VIVUS more than 8% lower to $20.98 on late volume of nearly 1.3 million. The Food and Drug Administration pushed back the Prescription Drug User Fee Act review date related to the new drug application for Qnexa, the company's proposed obesity drug, to July 17 from April 17.

Harmonic shares lost 4% to $4.76 on volume of more than 90,000, according to, after the maker of video equipment lowered its revenue and gross margin outlook for the first quarter. The company cited weak demand from its European customers as part of the reason for the diminished forecast.

-- Written by Michael Baron in New York.

>To contact the writer of this article, click here: Michael Baron.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
AA $11.17 0.00%
HLIT $3.46 0.00%
SVU $5.03 0.00%
VVUS $1.65 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs